retatrutide clinical trials results Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Eli Lilly infiltrates anti-obesity market

Individuals with personal or family history of Medullary Thyroid Cancer (MTC) or MEN2 Syndrome

Food And Drug Administration

Experience the weight loss success you've been working toward, with natural support that enhances everything you're already doing right

Contact your provider promptly if you experience severe or persistent effects

This high cost, along with limited manufacturing supply, means usage has remained mostly concentrated in wealthier countries (notably the US and parts of Europe) and among patients who can afford to pay

If nausea persists despite dietary changes, discuss it with your provider at your next check-in